Full year revenues expected to treble at Retroscreen Virology Group

AIM-listed Viral challenge and virometrics specialist Retroscreen Virology Group has published a trading update ahead of its year-end predicting a significant rise in its year-on-year revenues.

AIM-listed Viral challenge and virometrics specialist Retroscreen Virology Group has published a trading update ahead of its year-end predicting a significant rise in its year-on-year revenues.

The company expects to report sales for the year ending December 31st 2012 in excess of £13m compared to £4.27m for the twelve months until December 31st 2011. Gross margin and net loss are also expected to be ahead of market expectations.

The trading update published by the company stated that significant revenue growth was being achieved from Retroscreen's solid pipeline of Viral Challenge Model (VCM) client engagements.

More specifically, it added that: "The revenue growth is principally due to the increased number of quarantines conducted during 2012, together with the study set-up and volunteer recruitment for a number of new VCM engagements with quarantines due to commence in 2013."

Kym Denny, Chief Executive Officer at Retroscreen Virology Group, commented, "I am thrilled by our revenue growth and delivery against a robust VCM pipeline, which continues to build steadily with clients holding firm against their VCM quarantine reservations booked months ahead."

Denny added: "Retroscreen remains focussed on revenue growth, developing capacity and pioneering the VCM as a new way to conducting clinical trials in the development of drugs against virus. We are building solid foundations to scale our growth and it is tremendously fulfilling to see that the outcome of this investment will be reported in our 2012 financial results."

Retroscreen Virology Group's share price rose 8.16% to 132.50p at 09:17 on Wednesday morning.

MF

Recommended

The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
2 Feb 2023
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
23 Jan 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023
Investing trends to watch out for in 2023: what analysts say
Investment strategy

Investing trends to watch out for in 2023: what analysts say

What are sensible strategies for high inflationary times? We ask analysts to find out.
22 Dec 2022

Most Popular

Best savings accounts – February 2023
Savings

Best savings accounts – February 2023

Interest rates on cash savings are making a comeback. We look at the best savings accounts on the market now
3 Feb 2023
The best one-year fixed savings accounts - February 2023
Savings

The best one-year fixed savings accounts - February 2023

Earn almost 5% on one-year fixed savings accounts.
3 Feb 2023
After slumping 42% last year, what's next for Scottish Mortgage?
Investment trusts

After slumping 42% last year, what's next for Scottish Mortgage?

After a spectacular couple of decades, the Scottish Mortgage Investment Trust fell by 42% last year. We take a look at the trust's performance and dis…
3 Feb 2023